Ligand bias refers to the ability of a drug at a receptor to activate selectively particular cell signalling pathways over others, in a way that cannot be explained by traditional models of receptor theory. For a physiologically and therapeutically important GPCR (G-protein-coupled receptor) such as the MOPr (μ-opioid receptor), the role of ligand bias is currently being explored, not only in order to understand the molecular function of this receptor, but also with a view to developing better analgesic drugs with fewer adverse effects. In this short review, the ways to detect and quantify agonist bias at MOPr are discussed, along with the possible significance of MOPr ligand bias in the therapeutic use of opioid drugs. An important conclusion of this work is that attempts to define ligand bias at any GPCR on the basis of the visual inspection of concentration-response curves or comparison of maximum response (E max ) values can be misleading. Instead, reliable estimations of relative agonist efficacy are needed to calculate bias effectively.
Introduction
Classical ideas of GPCR (G-protein-coupled receptor) function describe drug action in terms of affinity and efficacy, where affinity reflects the tendency of the drug to interact with the receptor whereas efficacy describes the ability of the drug, once bound, to activate the receptor and produce a measurable response in the system studied. This school of thought also suggests that a GPCR can exist in either an active or inactive state, with the former being stabilized by agonist binding; this is sometimes referred to as the two-state model [1] . More recently, increasing evidence suggests that a GPCR is able to exist in more than one active state or conformation [2] [3] [4] , and that different ligands may be better at stabilizing one active state than another. This phenomenon has been termed 'ligand bias', but 'functional selectivity', 'liganddirected signalling' and other terms are also widely used [5, 6] . Advances in the assays for measuring cell signalling pathways mean that it is now possible to measure multiple signalling outputs following activation of a receptor by a ligand, enabling the detection of ligand bias. However, it is important to undertake rigorous analysis of such data as otherwise the wrong conclusions can be formed about whether a ligand shows bias or otherwise. Ligand bias is an important potential drug property, as it can enable the identification and development of ligands that may be better able to produce therapeutic effects and less able to induce adverse effects of drug treatment. Clear examples of ligand bias at GPCRs that may have therapeutic applications have been observed [7] , for example, with parathyroid hormone receptors [8] , angiotensin II type 1 receptors [9] and GPR109A (niacin receptor 1) receptors [10] . It seems likely that ligand bias is an area of pharmacology and cell signalling that will continue to grow for the foreseeable future.
How can bias be investigated?
To detect biased agonism, it is necessary first of all to have assays of the relevant signalling outputs from a defined GPCR that will allow the generation of good quality concentrationresponse curves. Ideally, the responses need to be measured in the same cell type to avoid complicating factors such as differences in receptor expression levels or in post-receptor coupling efficiency between cell types. The responses recorded can be any signalling output for the receptor, such as [ 35 S]GTP[S] (guanosine 5 -[γ -thio]triphosphate) binding, ion channel modulation, second messenger generation, arrestin recruitment, receptor phosphorylation or internalization. Actually the response measured can even be confined to the receptor itself since there are now techniques including FRET (fluorescence resonance energy transfer) [11] and NMR spectroscopy [4] to measure more directly agonist-induced conformational changes of the receptor protein. Whereas ligand bias is normally considered between G-protein-and arrestin-dependent signalling pathways, it should be noted that bias can also be evident between different G-protein subunits [12] , different arrestin isoforms [13] or any other signalling output that can be measured.
It is possible to detect cases of overt bias by simple examination of concentration response curves; in Figures 1(A) and 1(B), activation of a single receptor type in the cells leads to two responses, cAMP and inositol phosphate generation. Agonist 1 is more potent than agonist 2 at generating cAMP ( Figure 1A ), but is less potent than agonist 2 at stimulating inositol phosphate accumulation ( Figure 1B) . Such data cannot be explained by classical receptor theory, but is instead explained by supposing that the two agonists stabilize different active conformations of the receptor, which The two ligands shown are agonists at this receptor, but in (A) agonist 1 is more potent for the cyclic AMP response whereas in (B) agonist 2 is more potent for the inositol phosphate response. This is a clear example of biased agonism; either agonist 1 is biased towards the cAMP pathway and/or agonist 2 is biased towards the inositol phosphate pathway. (C) For analysis of a series of agonist concentration-response curves, the data are globally fitted to the equation of the operational model [15] . In the equation, E is the agonist response, E max is the maximum possible tissue response to the agonist, n is the slope factor of the receptor-response transducer function, [A] is the agonist concentration, K a is the equilibrium dissociation constant of the drug-receptor interaction, and τ is the operational efficacy, which is defined as R T /K e , where R T is the receptor concentration and K e the concentration of the agonist-receptor complex that produces a half-maximal response (note K e is not the same thing as the EC 50 ). The relative τ values are a measure of relative efficacy for the agonists at that receptor in the cells or tissue in question.
couple differentially to these two pathways. Perhaps small differences in the shape of the intracellular loops and Cterminus of the GPCR lead to differential interaction with intracellular signalling proteins. However, bias is not usually as obvious as in Figures 1(A) and 1(B) , so effective ways to detect bias are required. From the concentration-response curves, it may be possible to use the maximum agonist response (E max ) values alone to assess bias, but this can confuse interpretation and lead to erroneous conclusions. This is in part because the E max of an agonist is in many cases not just dependent on agonist efficacy, but can be determined by the limits of the response being measured in the cells, such as, for example, the concentration of G-protein, adenylate cyclase or phospholipase C. Thus two agonists can have quite different values of efficacy yet give the same maximum response in a cell or tissue. In assays where there is efficient coupling between receptor occupation and response, often seen for example in assays of cAMP accumulation, the E max for many agonists will be the same, i.e. a tissue-limited maximum, and thus comparison of E max values is in many cases an inadequate test for agonist relative efficacy and hence bias.
To properly test for biased agonism, the best approach is to obtain values of relative efficacy of the ligands for the responses being measured. The relative efficacy of agonists can be obtained by analysis of concentration-response data using one of several methods [14] [15] [16] [17] . In our initial analysis of ligand bias at MOPr (μ-opioid receptor) [18] , we used operational modelling developed by Black and Leff [15] to obtain relative values of efficacy of a series of ligands for signalling outputs at MOPr. This method is based upon the idea that a mathematical model can be used to explicitly describe the relationship between agonist concentration and response obtained. The rapid growth in the area of quantitative pharmacology means that newer, perhaps better, ways to detect and quantify ligand efficacy and bias are regularly being suggested [19, 20] .
For the analysis of ligand bias at MOPr, the signalling outputs we initially chose [18] were ligand-activated increases in [ 35 S]GTP[S] binding (as a measure of G-protein activation) and ligand-activated recruitment of arrestin-3 to the MOPr (as a measure of arrestin-dependent signalling pathways). Both assays were undertaken in HEK (human embryonic kidney)-293 cells stably expressing MOPr. The arrestin-3 recruitment was measured using a β-galactosidase complementation assay (PathHunter ® assay from DiscoverX) [21] .
The key property of these two assays was that they enabled the generation of robust concentration-response curves for a large number of agonists, with well-defined E max values.
Global fitting of the concentration-response data for all the ligands to the equation of the operational model ( Figure 1C ) can be undertaken in a data analysis package such as the recent versions of GraphPad Prism, which in fact already contains the equation for the operational model. In order to fit the data, estimates of the equilibrium K a (dissociation constant) for each ligand must be supplied, which can be obtained from binding assays using membranes of the same cells [18] (NB since the conditions of the binding assay such as GTP and Na + concentration can affect the actual value of agonist K a , this could significantly affect the efficacy values obtained from operational analysis; however, we reasoned that the conditions of the binding assay would be the same for all ligands examined and thus probably not significantly affect relative efficacy values). From this operational analysis the relative efficacy values of the agonists were obtained for each of the two signalling outputs in the form of relative τ values [18] . These results indicated that for the more than 20 MOPr ligands studied, there was a wide range of τ values for [ 35 S]GTP[S] binding and for arrestin-3 recruitment. This is intriguing because many of the opioid ligands are employed as effective analgesics even though they appear to have widely different efficacies for downstream signalling. Furthermore, the τ value for [ 35 S]GTP[S] binding for each agonist was in all cases higher than the respective τ value for arrestin-3 recruitment. This indicates that the efficacy of ligand-induced MOPr coupling to G-protein is greater than that for coupling to arrestin, which is probably owing to amplification being present in the former but not the latter pathway. It also illustrates the important point that when a ligand occupies a receptor, it can exert distinct efficacies for the downstream signalling outputs.
How can bias be quantified?
Given that the experimental approach described above leads to reliable measures of relative efficacy i.e. relative τ values for more than one signalling output from a receptor, how is the data to be treated in order to detect bias? A simple approach that we have used [18] is to plot the relative efficacy values for the two readouts against each other and use linear regression to determine how well the values are correlated. The idea is that if the correlation is good then ligand bias is not evident, with the plot simply indicating that the better a ligand is at activating one pathway, the better it is at activating the other. On the other hand, if there is a poor correlation (assuming the τ values have been obtained from reasonably good data), this provides evidence of bias since the different ligands have differential abilities to promote coupling to the two downstream signalling outputs. When this analysis was undertaken with our data for MOPr ligands (Figure 2A) , we found that in general, there was a good correlation with a reasonably high value for r 2 from the linear regression [18] . However, it was also evident that some ligands, and in particular the endomorphins, lay away from the linear regression line and towards the axis for arrestin-3 recruitment, suggesting that these ligands may be arrestin- biased. Indeed, when endomorphin was omitted from the correlation analysis, the r 2 value of the linear regression increased dramatically ( Figure 2B) .
Although we were able to make suggestions about the bias of ligands from these data, it became clear that a rigorous quantitative analysis of bias was needed to identify ligands as biased or balanced. A suitable method to do this had recently been described [19] and we were able to use this approach to attempt to identify biased ligands from our MOPr data for G-protein and arrestin signalling outputs. The method involves calculating the effective signalling for a ligand (σ lig ) by the expression σ lig = log(τ lig /τ ref ) where the τ value for a particular ligand for a signalling pathway (pathway 1) is compared with that of a reference, unbiased (balanced) ligand in the same signalling pathway. If this is repeated for another signalling output (pathway 2), then a bias factor (β) is calculated by β lig = {σ lig(pathway1) − σ lig(pathway2) }/ √ 2. For our data, we chose Leu-enkephalin as the reference unbiased ligand (Figure 2 ). When this analysis of bias [22] was undertaken for all the opioid ligands tested, endomorphin-2 was found to be significantly biased towards arrestin. Importantly, it was apparent that a spectrum of MOPr ligand bias for G-protein/arrestin could be observed when the bias factors of all the ligands were considered (see Figure 8 in [22] ). These results were of some interest since ligands such as endomorphin-2 had not previously been highlighted as arrestin-biased ligands. On the other hand, a ligand such as morphine, which is generally considered to be biased away from arrestin interaction, appeared as a balanced ligand in our analysis [18, 22] with, relative to other agonists such as Met-enkephalin and fentanyl, low efficacy for both G-protein coupling and for arrestin-3 recruitment (Figure 2) .
How is it possible that a ligand such as morphine can be classed as an unbiased ligand when it is able to strongly activate many G-protein-coupled responses [23, 24] approximately the same for the two agonists (∼25 for each agonist; note that for the arrestin-biased ligand endomorphin-2 the ratio falls to 6). However, the absolute τ value for morphine-induced arrestin-3 recruitment is low (0.22) and so the agonist behaves similarly to a very weak partial agonist in this assay, whereas the τ for methadone-induced arrestin-3 recruitment is higher (0.67) and is sufficient to produce the tissue E max for this assay. In other words, even though the difference between two agonists in terms of their concentration-response curves for two signalling outputs can look very different, this does not necessarily equate to bias. This is an area of significant misunderstanding among those investigating drug action, but these results [18, 22] show clearly that estimation of agonist relative efficacy with subsequent quantification of bias is the best way for the experimenter to identify biased ligands at a GPCR [16, 19, 20] .
Phosphorylation of MOPr and ligand bias
Since arrestin recruitment to most GPCRs is in part dependent on agonist-induced phosphorylation of the receptor [25] [26] [27] , then an explanation for arrestin bias of a ligand could be the extent and/or site on the receptor of phosphorylation induced by that particular ligand. To investigate this for MOPr, we used an antiphosphoreceptor antibody to quantify the phosphorylation status of the Ser 375 residue ( Figure 3B ), which has been associated with GRK (G-protein-coupled receptor kinase) phosphorylation of the receptor as well as receptor desensitization and internalization [28, 29] . Subsequent operational analysis of the phosphorylation concentration-response data revealed that, unlike its ability to couple to G-protein, endomorphin had a relatively high efficacy (τ ) for inducing Ser 375 phosphorylation [22] . Thus the arrestin bias of endomorphin-2 at MOPr is probably explained by its ability to induce efficient phosphorylation of MOPr, and thus efficient arrestin-3 recruitment to the receptor. Recent studies [30] [31] [32] [33] , including our own [34] using MS to identify phosphorylation sites in the C-terminal tail of MOPr have identified multiple phosphoacceptor sites (see Figure 3B ). Of particular interest was the observation [30] that whereas the high efficacy agonist DAMGO ([D-Ala 2 -MePhe 4 -Gly(ol) 5 ]enkephalin) was able to induce phosphorylation of three residues (serine, threonine and threonine) in the Ser 375 -Thr-Ala-Asn-Thr motif in the C-terminal tail, morphine could only induce detectable phosphorylation of the serine residue in this motif. Thus morphine's poor ability to recruit arrestin-3 and induce MOPr internalization may be because it weakly induces phosphorylation of Ser 375 and is unable to induce phosphorylation of Thr 376 and Thr 379 . Perhaps endomorphin-2 for whatever reason is instead able to induce robust phosphorylation of these three residues in the STANT motif. Equally it is possible that endomorphin-2 and possibly other agonists are able to induce differential phosphorylation of the other sites identified in the C-terminus of MOPr ( Figure 3B ). At present, we are investigating this intriguing possibility, which is an important line of enquiry since the function of phosphorylation of multiple sites in the C-terminus and potentially other intracellular regions of MOPr is not clear.
What is the mechanism of ligand bias?
A key question is: how do different ligands interact with GPCRs such that distinct signalling output profiles are generated? Many have concluded that the ligands are able to stabilize distinct active conformational states of the receptor. Although distinct, these active conformations would have overlapping features that facilitate coupling to the same downstream effectors, however the precise coupling to each individual output may vary from ligand to ligand. At the present time, little is known about the conformational differences in a GPCR induced by a balanced compared with a biased ligand, but this is hardly surprising given that the differences in conformation between active and inactive GPCR conformations are probably not as dramatic as at first expected [35, 36] . The crystal structure of MOPr was published recently [37] , but little information is available about conformational changes in response to a ligand; this will no doubt become a fertile area for future experimentation in the opioid field. Furthermore, advanced techniques including fluorescence spectroscopy [2, 11] and NMR spectroscopy [4] indicate ways in which ligand-induced changes in GPCR conformation can be studied in the future.
Therapeutic possibilities for ligand bias at MOPr
Ligand bias at MOPr is of potential importance with regard to the development of opioid ligands that produce analgesia but not the adverse effects associated with opioid drugs, such as constipation, nausea and vomiting, respiratory depression, as well as tolerance and dependence [38, 39] . If ligands with appropriate bias can be identified in cell signalling assays, then these can be tested in the appropriate models with a view to exerting the desired in vivo profile. However, whereas for some GPCRs it is clear how the G-protein compared with arrestin signalling pathways relate to the therapeutic versus adverse effect profile [7] , this is currently not at all clear for the MOPr. There is evidence that a G-protein-biased ligand such as herkinorin is an effective analgesic but does not lead to significant tolerance and dependence [40, 41] . On the other hand, drugs based on the structure of the endomorphins, which we reported to be arrestin-biased [18, 22] , appear to also have a favourable profile in ability to produce analgesia compared with the occurrence of adverse effects such as dependence [42, 43] . The picture is therefore complex and requires clarification.
An important step now will be to establish the precise signalling pathways and functional outcomes of activation of G-protein-and arrestin-dependent signalling following activation of MOPr in neurons. In addition to acute signalling events, the activation of arrestin-dependent signalling will also trigger longer-lasting events such as ERK phosphorylation and changes in gene expression [44] , effects that may have relevance for some of the longerterm adaptive changes seen following opioid administration. Although studies with arrestin-3-knockout mice [45, 46] have provided some answers, these studies have also raised many further questions. For example, why in some cases, is morphine-induced analgesia greater or longer lasting in arrestin-3-knockout mice compared with wild-type, whereas the analgesia induced by other agonists such as fentanyl and methadone is the same in arrestin-3 compared with wild-type mice [47] ? This observation was unexpected given the poor ability of morphine to recruit arrestins compared with the very efficient recruitment of arrestins by fentanyl and methadone. Furthermore, the role of arrestins in MOPr desensitization and resensitization in neurons is more complex than originally thought [48, 49] , and does not seem to comply with the classical model of GPCR regulation by GRKs and arrestins [27] . It is clear that much further work will be required to understand the role of G-protein compared with arrestin signalling in the actions of opioid drugs at MOPr in the intact organism [39] .
Conclusions
The detection of ligand bias at MOPr, and at GPCRs in general, can best be achieved using carefully constructed agonist concentration-response curves of signalling outputs. The use of appropriate methods to determine agonist relative efficacy from the curves is the best way to treat the data in order to determine bias. Furthermore, recently developed quantitative methods show that ligand bias at a GPCR can be assessed in a manner that enables statistical significance to be determined.
For the in vivo effects observed in response to ligands at MOPr, the overall response depends on a number of factors including the selectivity of the ligand for different opioid receptor subtypes, the pharmacokinetic profile of each ligand, and not least the ability of the ligand to interact with MOPr and produce cellular responses. Ligand bias adds a further level of complexity to the overall picture in that the cellular responses generated may vary depending on the ligand used. Therefore, in order to understand fully the actions of opioid drugs, it is essential that the precise cellular signalling patterns and bias of relevant ligands are determined. Finally, it will be important to identify the structural differences in the receptor that underlie ligand bias. Given the pace of GPCR structural studies [35, 36] , it is unlikely to be too long before significant light is shed on this area. 
